AMENDMENT NO. 2 TO LICENSE AGREEMENTLicense Agreement • March 16th, 2015 • Anthera Pharmaceuticals Inc • Pharmaceutical preparations • California
This Amendment No. 2 to the License Agreement (this “Amendment”) is made as of November 26, 2014, by and among Anthera Pharmaceuticals, Inc., a Delaware corporation (“Anthera”) and Amgen, Inc., a Delaware corporation (“Amgen”).
ANTHERA PHARMACEUTICALS, INC. STOCK PURCHASE AGREEMENTStock Purchase Agreement • March 16th, 2015 • Anthera Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Stock Purchase Agreement (the “Agreement”) is made and entered into as of December 11, 2014 (the “Effective Date”) by and between Anthera Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Zenyaku Kogyo Co., Ltd. (the “Purchaser”). Unless otherwise defined herein, all dollar amounts refer to U.S. dollars.
SUBSCRIPTION AGREEMENTSubscription Agreement • March 16th, 2015 • Anthera Pharmaceuticals Inc • Pharmaceutical preparations
This Subscription Agreement (this “Subscription”) is dated January 27, 2015, by and between the investor identified on the signature page hereto (the “Investor”) and Anthera Pharmaceuticals, Inc., a company incorporated and registered in the State of Delaware (the “Company”), whereby the parties agree as follows:
ContractDeferred Compensation Agreement • March 16th, 2015 • Anthera Pharmaceuticals Inc • Pharmaceutical preparations
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING...Collaboration and License Agreement • March 16th, 2015 • Anthera Pharmaceuticals Inc • Pharmaceutical preparations • California
This Collaboration and License Agreement (the “Agreement”) is entered into as of 11 December 2014 (the “Effective Date”), by and between Anthera Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware, USA (“ANTHERA”), having an address of 25801 Industrial Blvd., Suite B, Hayward, CA 94545, USA, and Zenyaku Kogyo Co., Ltd., a corporation existing and organized under the laws of Japan, having its registered offices at 5-6-15, Otsuka, Bunkyo-ku, Tokyo, Japan 1128650 (“ZENYAKU”).
SUBSCRIPTION AGREEMENTSubscription Agreement • March 16th, 2015 • Anthera Pharmaceuticals Inc • Pharmaceutical preparations
This Subscription Agreement (this “Subscription”) is dated January 27, 2015, by and between the investor identified on the signature page hereto (the “Investor”) and Anthera Pharmaceuticals, Inc., a company incorporated and registered in the State of Delaware (the “Company”). The Investor and the Company are parties to a Stock Purchase Agreement dated December 11, 2014 (the “Stock Purchase Agreement”) pursuant to which the Company has the right to direct the Investor to purchase registered shares of the Company’s common stock, $0.001 par value per share, on the terms specified in the Stock Purchase Agreement, by delivering notice to the Investor. Purchases of shares pursuant to the Stock Purchase Agreement are partial consideration for rights granted by the Company to the Investor under the parties’ Collaboration and License Agreement dated December 11, 2014 (the “License Agreement”). The Company delivered to the Investor the Initial Closing Notice (as such term is defined in the Stock
